Medicines · Safety9 November 2026·Verified source: FDA, EMA
Your eyes: a rare sign worth knowing
MounjaroOzempicWegovy
What changed
The US Food and Drug Administration (FDA) now requires all medicines in the GLP-1 class to mention a rare condition of the optic nerve, called NAION, in their prescribing information. In the FDA's analysis of 126 clinical trials, there were 6.4 cases per 100,000 people treated for a year, compared with 3.8 in the comparison groups.
What it means for you
- 1The sign to watch for: a sudden, painless loss of vision in one eye, sometimes noticed on waking. If it happens, see a doctor or an eye specialist the same day.
- 2The condition is rare. Do not stop treatment on your own; any change is decided with your doctor.
What does not change
In the European Union, the leaflets for semaglutide medicines (Ozempic, Wegovy) have listed NAION as a very rare side effect since 2025. The FDA decision applies to the US prescribing information.